Streetbeat News

Products Services

JAGX

Jaguar Health (NASDAQ:JAGX) has submitted an Orphan Drug Designation application to the FDA for crofelemer for cholera-related diarrhea. Crofelemer, a plant-based prescription drug, aims to treat moderate-to-severe diarrhea from various infections, including cholera. The company has previously received ODD for crofelemer for short bowel syndrome and microvillus inclusion disease. Jaguar expects results from 5 proof-of-concept studies in 2024 and 2025, with potential early patient access in Europe in 2025. The FDA activated an IND application for crofelemer in August 2023. ODD could provide development incentives and a seven-year marketing exclusivity in the U.S.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:35 pm

CSPI

ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPI), has secured a multi-million dollar contract with one of the world's largest pharmaceutical manufacturers to deploy its AZT PROTECT solution across over 40 global manufacturing facilities. This deployment aims to protect the pharmaceutical company's critical infrastructure from sophisticated cyberattacks targeting operational technology (OT). AZT PROTECT, launched in July 2023, is designed specifically for OT environments, offering advanced protection against zero-day and supply chain attacks without requiring continuous cloud updates.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:35 pm

MSAI

Infrared Cameras Holdings, Inc. has officially changed its name to MultiSensor AI Holdings, Inc. (MSAI) to better reflect its evolution into a SaaS leader in industrial predictive maintenance. This change is part of a broader transformation that includes a successful NASDAQ listing in December 2023, enhancements to its software platforms, and a new visual identity. The company's NASDAQ ticker symbol, MSAI, remains unchanged.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:33 pm

ABVC

ABVC BioPharma has been granted an Australian patent valid until 2040 for PDC-1421, a component of ABV-1504, aimed at treating Major Depressive Disorder. This development could enhance ABVC's intellectual property portfolio and potentially impact its market position in the treatment of depressive disorders.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:32 pm

CBAY

GILD

Gilead Sciences, Inc. (GILD) is set to acquire CymaBay Therapeutics, Inc. (CBAY) for $32.50 per share, totaling $4.3 billion. This acquisition adds seladelpar, a promising treatment for primary biliary cholangitis (PBC), to Gilead's liver disease portfolio. Seladelpar has received FDA priority review with an anticipated approval in Q3 2024. The transaction, expected to close in Q1 2024, is seen as neutral to Gilead's 2025 earnings and significantly accretive thereafter.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:31 pm

NVDA

Nvidia Corp's CEO, Jensen Huang, emphasized the importance of countries developing their own AI infrastructure to harness economic benefits and preserve cultural integrity. He highlighted Nvidia's role in democratizing AI access through advancements in AI computing efficiency, which has contributed to Nvidia's valuation soaring to $1.73 trillion. Huang criticized the fearmongering around AI and argued that advances in computing technology will reduce the costs associated with AI development, challenging the notion that $7 trillion is necessary for semiconductor initiatives. Nvidia is expanding its reach by launching a new division focused on designing custom chips for cloud computing, positioning itself against competitors like Broadcom and Marvell Technology.

Portfolio Pulse from Anusuya Lahiri

February 12, 2024 | 1:26 pm

SYRA

Syra Health Corp. (NASDAQ:SYRA) has secured a healthcare workforce contract with Fairfax County, Virginia, to provide 24-hour nursing care and staff other temporary healthcare positions. This marks the company's third active government contract in Virginia, emphasizing its role in healthcare staffing. The contract, which extends through June 30, 2028, with potential for renewal, will generate revenue based on staffing needs and hourly rates. Syra Health's commitment to enhancing healthcare through staffing solutions aligns with its mission to improve healthcare services.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:16 pm

SONY

Sony Group Corp (NYSE:SONY) is set to acquire a 50% stake in Michael Jackson's music catalog from his estate in a deal valued at over $600 million, the largest of its kind. The acquisition includes song shares, the Mijac publishing catalog, master recordings, and publishing rights. This move, along with the release of a biographical movie about Jackson, underscores the lasting commercial interest in his work. Sony reported an 8% year-on-year sales growth in Q2 FY23 and remains committed to its PlayStation and Spider-Man franchises.

Portfolio Pulse from Anusuya Lahiri

February 12, 2024 | 1:16 pm

AWH

Aspira Women's Health Inc. (NASDAQ:AWH), a company specializing in women's health diagnostic tools, announced a late-breaking poster presentation at the 71st Annual Scientific Meeting for the Society for Reproductive Investigation in Vancouver, Canada. The presentation will showcase foundational data for Aspira's EndoCheckSM, a noninvasive diagnostic test for endometriosis, specifically focusing on endometriomas. The event is scheduled for March 15, 2024, and involves collaboration with the Oxford Endometriosis CaRe Centre.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:15 pm

DXR

Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, announced two significant customer transactions for its BVA-100 Blood Volume Analyzer in January 2024. The deals include a four-year lease agreement with a network of 24 hospitals across several states and a purchase by a 200-bed hospital in Mississippi. Dr. Aaron Earles highlighted the BVA's impact on patient care, noting improvements in treatment outcomes. CEO Michael Feldschuh emphasized the company's focus on commercialization and expanding its customer base.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:15 pm